The oil-based, viscous, clear solution is deposited directly into the surgical wound bed prior to closure. Credit: THICHA SATAPITANON/Shutterstock.

Israel-based clinical-stage speciality pharmaceutical company PainReform has reported positive initial safety data from its ongoing Phase III bunionectomy study of PRF-110, a formulation for post-surgical pain.

The randomised, double-blind, placebo-controlled trial is designed to assess the efficacy and safety of PRF-110 in patients undergoing bunionectomy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The study enrolled a total of 443 patients across eight US clinical sites.

Initial safety data from the study indicated a reduced incidence of adverse events, with an average of just one per subject.

With this asset, the company intends to offer a new non-opioid solution for post-surgical pain management.

PRF-110 is based on the local anesthetic ropivacaine and is PainReform’s lead product, targeting the postoperative pain relief market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This oil-based, viscous, clear solution is deposited into the surgical wound bed directly before closure.

PainReform’s drug-delivery system offers an extended period of post-surgical pain relief, without repeated dose administration, to potentially reduce the need for opiates.

PainReform chairman and interim CEO Ehud Geller said: “We are highly encouraged by the early safety data from our Phase III bunionectomy study, which reinforces the potential of PRF-110 to be a game-changer in post-surgical pain management.

“The outstanding safety profile of PRF-110, which leverages the well-established safety of ropivacaine and generally recognised as safe (GRAS) formulation components, positions it as a promising non-opioid alternative in the post-operative pain market. This milestone marks a significant step forward in our mission to address the $12bn post-operative pain market with a safer and more effective therapeutic option.”